The Cognitive Function and Ageing Studies

Title of the cohort
The Cognitive Function and Ageing Studies
Acronym for cohort
CFAS
Name of Principal Investigator

Title Prof
First name Carol
Last name Brayne

Address of institution where award is held

Institution Institute of Public Health, University of Cambridge
Street Address Robinson Way
City Cambridge
Postcode CB2 0SR

Country

  • United Kingdom

Website
http://www.cfas.ac.uk
Contact email
[email protected]
1. The cohort includes, or expects to include, incidence of the following conditions

  • Alzheimer’s disease and other dementias
  • Parkinson’s disease
  • Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

  • Already possible

2a. Stated aim of the cohort
To find out how common dementia and associated conditions are in England and Wales and also, how many new cases of dementia develop each year
2b. Features distinguishing this cohort from other population cohorts

3a. i) Number of publications that involve use of cohort to date
190
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)
http://www.cfas.ac.uk/pages/publications/searchpub.asp
3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from: 65
To (‘until death’ if applicable): No limit

4b. Study criteria: inclusion criteria
The CFAS are population based studies of individuals aged 65 years and over living the community, including institutions. The fieldwork for this study began in 1991.
4c. Study criteria: exclusion criteria
N/A
5. Size of the cohort (i.e. number of participants enrolled)

  • 10,001 – 15,000 participants

6a. Measures used to characterise participants

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

  • No

7. Study design

  • Prospective cohort
  • Longitudinal
  • Other (please specify)
  • The follow-up has been determined by funding and the design of associated bolt-on studies.

8. Cases matched by

  • Other health assessment (specify) / N/A

9a. Does the study include a specialised subset of control participants

  • No

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-01-1989
10a. ii) Data collection end date

10a iii) Data collection for this study is

  • Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

  • Yes – funding applied for

11. Data collected

  • Only through the study

12. System in place to enable re-contact with patients for future studies

  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database
Database is web-based
Database on spreadsheet  Yes STATA
Database is on paper
Other (specify)

 
Language used:
English
13b. Format and availability of data held as individual records

Yes/No % available
Data held as individual records
Data is web-based
Data held on computer based records  Yes
Data held on cards
Other (specify)

Language used:
English
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups

  • Apply to PI or co-ordinator at resource
  • Access Committee mechanism

15. Data sharing policy specified as a condition of use

  • Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA

  • Post-mortem donors: brain
  • Living donors:blood

16b. ii) Form available tissues/samples/DNA are supplied in

  • Primary Samples: Stabilised samples (frozen or fixed)

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups

  • No

The Cognitive Function and Ageing Studies

Population Cohorts
United Kingdom
Alzheimer’s disease & other dementias|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders
2011

 

 

Post
Filter